PDE6D and cancer: Novel small molecule inhibitors (i.e., “deltarasin” and “deltazinone 1”), which bind to the prenyl-binding pocket of PDE6D, impair the enrichment of RAS proteins at the plasma membrane [17,21], thereby inhibiting RAS activation, which has been considered a desirable goal in cancer research for a long time.